The ADA position paper in 2022 endorsed screening for HF among individuals with T2DM with risk factors for HF, and the 2024 ADA guidelines endorsed annual screening for people with T2DM for HF using a biomarker, most notably NT-proBNP. The gene discussed is NPPB; the disease is hydrops fetalis.